X @The Wall Street Journal

Two developments Thursday–Eli Lilly’s strong quarterly performance and Novo Nordisk’s unsolicited $9 billion bid for a startup–show why drugmakers can’t get enough of weight loss https://t.co/MpVV3xS7ei ...